ENBREL(R) FIRST THERAPY SUBMITTED TO FDA SHOWING INHIBITION OF BONE AND JOINT DAMAGE IN PSORIATIC ARTHRITIS PATIENTS
FOR IMMEDIATE RELEASE
THOUSAND OAKS, Calif., October 24, 2002 -- Amgen (NASDAQ:AMGN) today announced that it has submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) to further expand the use of ENBREL(R) (etanercept) to inhibit the progression of structural damage in psoriatic arthritis patients. ENBREL is the first and only approved therapy to treat active arthritis in patients with psoriatic arthritis and has been shown to improve the psoriatic skin lesions associated with the disease.
"In clinical trials, patients with psoriatic arthritis taking ENBREL showed a significant improvement in each area of measurement related to bone and joint damage, including total Sharp score, joint erosion score and joint space narrowing," said Daniel Burge, MD, Amgen vice president of clinical research. "We're encouraged by the magnitude of improvement produced by treatment with ENBREL for 12 months."
The sBLA is based on the results of a 12-month, double blind, placebo controlled trial. The study results will be presented in a plenary session at the 66th Annual American College of Rheumatology Scientific Meeting in New Orleans.
Also under review is an sBLA recently filed by Amgen for the use of ENBREL to improve physical function in patients with rheumatoid arthritis (RA). ENBREL has the broadest range of indications of any biologic therapy in rheumatic diseases. It is currently approved to reduce the signs and symptoms in patients with moderately to severely active RA. It is also indicated to inhibit the progression of bone and joint damage in patients with moderately to severely active RA. Additionally, ENBREL is the only anti-TNF therapy approved:
- To be used without methotrexate to treat patients with moderately to severely active RA;
- To treat patients 4 years of age and older with moderately to severely active polyarticular-course juvenile rheumatoid arthritis who have had an inadequate response to DMARDs
- To treat newly diagnosed RA patients with moderately to severely active disease; and
- To treat active arthritis in patients with psoriatic arthritis.
Approved since 1998, ENBREL has been used to treat more than 129,000 patients.
ABOUT PSORIATIC ARTHRITIS
Psoriatic arthritis is a distinct, chronic inflammatory disease of the joints and connective tissue. The disease combines joint pain and swelling that can lead to crippling debilitation, with psoriasis, an inflammatory skin disorder characterized by frequent episodes of redness and itching; thick, dry, silvery scales on the skin; and nail abnormalities. There are approximately 450,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50.
ENBREL is the only fully human TNF receptor approved for use to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis, and to reduce the signs and symptoms and inhibit the structural damage in patients with moderately to severely active RA. ENBREL is the only biologic therapy approved to treat newly diagnosed RA patients with moderately to severely active disease, and can be used alone.
ENBREL acts by binding TNF, one of the dominant inflammatory cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that causes the inflammatory process of psoriatic arthritis and RA. The binding of ENBREL to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.
ENBREL is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis; reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients 4 years of age and older who have had an inadequate response to one or more DMARDs; and reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.
Important Treatment Considerations
SINCE THE PRODUCT WAS FIRST INTRODUCED, SERIOUS INFECTIONS, SOME INVOLVING DEATH, HAVE BEEN REPORTED IN PATIENTS USING ENBREL. MANY OF THESE INFECTIONS OCCURRED IN PATIENTS WHO WERE PRONE TO INFECTIONS, SUCH AS THOSE WITH ADVANCED OR POORLY CONTROLLED DIABETES. RARE CASES OF TUBERCULOSIS HAVE ALSO BEEN REPORTED. ENBREL SHOULD BE DISCONTINUED IN PATIENTS WITH SERIOUS INFECTIONS. DO NOT START ENBREL IF YOU HAVE AN INFECTION OF ANY TYPE OR IF YOU HAVE AN ALLERGY TO ENBREL OR ITS COMPONENTS. ENBREL SHOULD BE USED WITH CAUTION IN PATIENTS PRONE TO INFECTION. CONTACT YOUR PHYSICIAN IF YOU HAVE ANY QUESTIONS ABOUT ENBREL OR INFECTIONS.
There have been reports of serious nervous system disorders such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes. Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL(R) (etanercept). There have also been rare reports of serious blood disorders, some involving death. Contact your doctor immediately if you develop symptoms such as persistent fever, bruising, bleeding, or paleness. It is unclear if ENBREL has caused these nervous system or blood disorders. If your doctor confirms serious blood problems, you may need to stop using ENBREL.
The most frequent adverse events in placebo-controlled RA clinical trials involving 349 adults were injection site reactions (ISR) (37%), infections (35%), and headache (17%). Only the rate of ISR was higher than that of placebo. The most frequent adverse events in a methotrexate-controlled clinical trial of 415 adults with early-stage RA were infections (64%), ISR (34%), and headache (24%). Of these, only the rate of ISR was higher than that of methotrexate. Patients have been observed in clinical trials for over 3 years. The incidence of malignancies has not increased with extended exposure to ENBREL and is similar to the projected background rate.
Adverse events in the psoriatic arthritis trial were similar to those reported in RA clinical trials.
In a study of 69 patients with JRA, infections (62%), headache (19%), abdominal pain (19%), vomiting (13%), and nausea (9%) occurred more frequently than in adults. The types of infections reported in JRA patients were generally mild and consistent with those commonly seen in children. Serious adverse reactions reported rarely were chicken pox (3%), gastroenteritis (3%), serious infection (2%), depression/personality disorder (1%), skin ulcer (1%), inflammation in parts of the upper digestive tract (1%), and diabetes (1%).
Please see full Product Information.
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, (NYSE: WYE), market ENBREL in North America. Other Wyeth affiliates market ENBREL outside of North America. Immunex Corporation manufactures ENBREL. Additional information about ENBREL, including full Prescribing Information, can be found on the Web site sponsored by the companies at www.enbrel.com or by calling toll free 888-4ENBREL (888-436-2735).
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent Form 10-Q. Amgen conducts research in the biotechnology/pharmaceutical field where movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.
Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. In addition, sales of our products are affected by reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers. These government regulations and reimbursement policies may affect the development, usage and pricing of our products.
In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.
Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Amgen. Amgen is providing this information as of October 24, 2002, and expressly disclaims any duty to update information contained in this press release.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.
# # #
Contact: Amgen, Thousand Oaks
Rebecca Hamm, 805/447-3875 (media)
Cary Rosansky, 805/447-4634 (investors)
An electronic version of this news release may be
accessed via our web site at http://www.amgen.com.
Visit the Corporate Center and click on Amgen News. Journalists and media representatives may sign up
to receive all news releases electronically at time of announcement by filling out a short form in the
Amgen News section of the web site.